NewsLatest News

bt_bb_section_bottom_section_coverage_image
Conference Highlights: Microbiome Connect USA

Introduction Kisaco Research’s flagship Microbiome Connect event returned to Boston in November. Joined by a range of microbiome companies and researchers, the event covered both the R&D and manufacturing considerations for microbiome drug development. From freeze-drying techniques for LBP development to synthetic therapeutic approaches, the conference platformed a diverse topic roster.   Some highlights of...

Targeting the Vaginal Microbiome to Develop Novel Therapeutics

The vaginal microbiota plays a key role in regulating vaginal health. Unlike other human microbiomes where bacterial diversity is positive, a healthy vaginal microbiota is associated with Lactobacillus species dominance. Lactobacillus spp. maintain vaginal community composition through lactic acid production and epithelial binding, protecting the host from pathogenic species. In 2002 the first study using...

A roundup of research on the gut-kidney axis and new microbiome therapeutics

Within the body’s renal system, the kidneys are the main players. Each person’s kidneys manage to filter around 200 litres of fluid per day, working to remove toxins from the blood, balance electrolytes, keep a consistent amount of water in the body, and secrete essential hormones. In the past decade, scientists have looked at how...

Conference Highlights: Microbiome Connect Europe

The Microbiome Connect Europe event, by Kisaco Research, was held recently in Amsterdam, the Netherlands. The speakers covered many facets of microbiome-focused products: discovery, clinical validation and mechanisms of action, commercial development, and manufacturing. Despite several high-profile microbiome companies facing closure during the past year, the industry remains strong—the conference showcased many diverse and promising...

Highlights of Pharmabiotics 2022: New therapeutics and regulatory directions

An in-person event, Pharmabiotics 2022, brought together individuals from academia and industry in the microbiome field to focus on how microbiome-based drug products will become a therapeutic reality in Europe. The event was hosted by PRI, an organization dedicated to navigating the regulation of microbiome medicinal products in Europe, using a collaborative approach to improve...

Understanding the gut-liver axis leads to microbiome-focused therapeutic options for liver diseases

Companies are now targeting the gut microbiome with therapies for fatty liver disease, hepatic encephalopathy, and more.. The liver is an incredibly complex organ—and its functioning leaves very little room for error. Even minor inflammation in the liver, caused by viral disease or other factors, interferes with the liver’s crucial activities of detoxification, synthesis, and...

The latest updates from the microbiome drug development field in Europe

A virtual event held earlier this year, Microbiome Movement – Drug Development Europe 2022, provided a chance to bring together the microbiome drug development community to share updates and discuss current challenges in the field. This brief report covers some of the take-homes from the event. Interestingly, scale-up and manufacturing were identified as key challenges...

A roundup of microbiome-targeting interventions for inflammatory bowel disease

Of all the diseases and conditions linked to the gut microbiome, the inflammatory bowel diseases (IBDs) ulcerative colitis and Crohn’s disease have been some of the most promising indications for potential therapeutics. Not only did early studies show robust differences in gut bacterial communities between those with IBD and healthy controls, but also, the observed...

Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière française du microbiote

Lyon- France – le 20 janvier 2022 – Créée en mars 2021, APM, qui compte 22 membres, est le fruit de l’union d’acteurs publics et privés engagés dans la promotion de la science émergente du microbiote. Porte-parole et fédérateur des acteurs majeurs du développement, de la production et de la commercialisation d’innovations thérapeutiquesliées au microbiote...

Improving respiratory health through live biotherapeutic products

Of all the respiratory diseases, one of them – COVID-19 – has been the focus of most of the research and attention over the past two years. While surely justified, this has had the effect of diverting resources away from the study of chronic respiratory diseases that urgently require solutions for clinical unmet needs: chronic...